Chemical Science

ROYAL SOCIETY OF CHEMISTRY

EDGE ARTICLE

View Article Online
View Journal | View Issue

Cite this: *Chem. Sci.*, 2025, **16**, 1233

All publication charges for this article have been paid for by the Royal Society of Chemistry

Stereodivergent assembly of δ-valerolactones with an azaarene-containing quaternary stereocenter enabled by Cu/Ru relay catalysis†

Kui Tian,‡[a] Zhuan Jin,‡[a] Xin-Lian Liu,[a] Ling He,[a] Hong-Fu Liu,[a] Pin-Ke Yu,[a] Xin Chang,[a] Xiu-Qin Dong *[a] and Chun-Jiang Wang *[ab]

Received 31st August 2024
Accepted 2nd December 2024

DOI: 10.1039/d4sc05852f

rsc.li/chemical-science

Developing methodologies for the expedient construction of biologically important δ-valerolactones bearing a privileged azaarene moiety and a sterically congested all-carbon quaternary stereocenter is important and full of challenges. We present herein a novel multicatalytic strategy for the stereodivergent synthesis of highly functionalized chiral δ-valerolactones bearing 1,4-nonadjacent quaternary/tertiary stereocenters by orthogonally merging borrowing hydrogen and Michael addition between α-azaaryl acetates and allylic alcohols followed by lactonization in a one-pot manner. Enabled by Cu/Ru relay catalysis, this cascade protocol offers the advantages of atom/step economy, redox-neutrality, mild reaction conditions, and broad substrate tolerance. Scale-up experiments and synthetic transformations further demonstrated the potential for synthetic applications. Mechanistic experiments support the envisioned bimetallic relay catalytic mechanism, and the key role of Cs_2CO_3 in promoting lactonization was also revealed.

Introduction

The stereoselective incorporation of all-carbon quaternary stereocenters into privileged heterocyclic molecular architectures to enhance three-dimensional complex geometries represents a significant objective in organic and medicinal synthesis as increased saturation and complexity often lead to increased biological activity and benefit drug discovery.[1] Ubiquitous δ-valerolactones (Scheme 1a), especially in enantioenriched forms, are crucial subunits of numerous natural products[2] and various molecules of pharmaceutical interest that display a wide range of biological properties, including antibacterial,[3] antiviral,[4] anticancer,[5] and cholesterol-lowering agents (HMGR inhibitors).[6] Two of the world's best-selling statin drugs, Lipitor and Zocor, contain a β-hydroxy-δ-valerolactone skeleton or its ring-opening δ-hydroxy carboxylate moiety.[7] In addition, δ-valerolactones are also synthetically useful building blocks, such as the Prelog-Djerassi lactone, for the preparation of important bioactive compounds.[8] Due to the



Scheme 1 Background information.

[a]Hubei Research Center of Fundamental Science-Chemistry, Engineering Research Center of Organosilicon Compounds & Materials, Ministry of Education, College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, Hubei, 430072, China. E-mail: xiuqindong@whu.edu.cn; cjwang@whu.edu.cn

[b]State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Shanghai, 230021, China

† Electronic supplementary information (ESI) available. CCDC 2375149. For ESI and crystallographic data in CIF or other electronic format see DOI: https://doi.org/10.1039/d4sc05852f

‡ These two authors contributed equally.

pharmacological importance and synthetic utility of optically active δ-valerolactones bearing multiple stereocenters, there has been a growing interest in asymmetric preparation of such compounds in the last few decades. Various strategies have been developed to synthesize chiral δ-valerolactones;[9] however, stoichiometric amounts of chiral auxiliaries and/or multiple-step sequences are generally required to achieve such chiral molecules as only one stereoisomer or its enantiomer.[10] It is well-known that different stereoisomers of chiral molecules always exhibit different biological activities, which are closely related to their stereochemical configurations. Therefore, it is necessary to develop convenient and step-economical methods for the stereodivergent synthesis[11] of all stereoisomers of chiral δ-valerolactones bearing multiple stereocenters, which is conducive to elucidating the relationship between molecular configurations and biological activities and discovering new drugs.[12] Most recently, Zhang and co-workers developed a creative bimetallic Ru/Ru sequential catalysis for asymmetric hydrogenation of α-methylene δ-keto carboxylic acids, and achieved the only example of stereodivergent synthesis of chiral δ-valerolactones containing 1,4-non-adjacent tertiary/tertiary stereocenters[13] (Scheme 1b). On the other hand, pyridine, as a privileged azaarene skeleton, is the most common nitrogen heterocycle among the 321 unique new small-molecule drugs approved by FDA (2013–2023).[14] We envisioned that combining two biologically important δ-valerolactone and azaarene motifs into a single new three-dimensional molecule with saturation and complexity through a linchpin of all-carbon quaternary stereocenters would introduce some unprecedented benefits to enhance potency, selectivity, and other drug-like properties.[1b] To our knowledge, there is no efficient method that enables stereodivergent construction of δ-valerolactones with an azaarene group contained within a α-quaternary stereocenter in a convenient and step-economical manner.

Borrowing-hydrogen (BH) catalysis has emerged as a convenient and atom-economic relay catalytic protocol for preparing structurally important chiral molecules starting from easily available alcohols in recent years,[15] and this process generally includes three steps: hydrogen borrowing, the reaction of the activated intermediate, and hydrogen returning. In continuation of our interest in stereodivergent synthesis[16] and recent achievements in BH-involved bimetallic relay catalysis,[17,18] we envisaged that orthogonally merging asymmetric borrowing-hydrogen catalysis and chiral Lewis acid catalysis with allylic alcohols and α-azaaryl acetates, to execute a one-pot dehydrogenation(HT)/Michael addition(MA)/hydrogenation(HG)/lactonization cascade process,[19] could offer the opportunity to achieve stereodivergent synthesis of chiral δ-valerolactones with an azaazrene-containing α-quaternary stereocenter and a tertiary stereocenter. As shown in Scheme 1c, the racemic branched allylic alcohol substrate **I** undergoes oxidative dehydrogenation with the aid of a chiral borrowing-hydrogen Ru-catalyst to form the active α,β-unsaturated ketone **II** and chiral Ru-hydride species, and the former reacts with the nucleophilic α-azaaryl acetate **III** ligated by chiral Cu-Lewis acid to give the corresponding Michael addition intermediate **IV**; the ensuing chiral Ru-hydride-enabled asymmetric reduction of the carbonyl group followed by spontaneous δ-lactonization delivers enantioenriched α-azaaryl-containing δ-valerolactones **VI** bearing 1,4-nonadjacent tertiary and quaternary stereocenters in a stereodivergent manner. Although theoretically feasible, there are still some challenges in this design: (1) the potential coordination of the N-heteroarene group in the α-azaaryl acetate substrate may cause deactivation of the borrowing-hydrogen Ru-catalyst; (2) undesired background reactions in the Michael addition step, the annulation efficiency of lactonization, and the potential overreduction[20] of the resulting δ-valerolactones into 1,5-diols; (3) the feasibility of stereoselectivity control enabled by this Cu/Ru relay catalysis, since the sterically congested quaternary stereocenter formed in the preceding Michael addition step has potential impact on the asymmetric induction of the following reductive hydrogenation.

Herein, we uncover a concise methodology enabled by bimetallic copper/ruthenium relay catalysis, which orthogonally merges borrowing hydrogen and Michael addition followed by lactonization. This cascade process circumvents substrate pre-activation, intermediate isolation and purification to realize the stereodivergent and rapid synthesis of highly functionalized chiral δ-valerolactones with an azaazrene-containing α-quaternary and a tertiary stereocenter in good yields with excellent stereoselectivity control. This protocol features step economy, redox-neutrality, high atom economy,[21] and the precise synthesis of all four stereoisomers of otherwise inaccessible chiral δ-valerolactones with 1,4-nonadjacent stereocenters from the same set of readily available starting materials.

Results and discussion

Optimization of reaction conditions

To verify the feasibility of the designed protocol, we began to investigate the cooperative Cu/Ru bimetallic relay catalysis for the cascade dehydrogenation/1,4-Michael addition/hydrogenation/lactonization process between the model substrates phenyl allylic alcohol **1a** and methyl 2-(pyridin-2-yl)propanoate **2a**. To our delight, the expected δ-valerolactone product **3a** was obtained in good yield with high diastereoselectivity and excellent enantioselectivity using the Cu(I)/**L1** and [Ru]-**1** catalytic system with THF as the solvent and Cs_2CO_3 as the base (76% yield, 16 : 1 dr, >99% ee, Table 1, entry 1). A series of chiral ferrocene-based P,N-ligands (**L2–L5**) and the chiral diphosphine ligand (*S*,*S*)-Ph-BPE **L6** for the copper complex were then examined, and ligand **L5** derived from chiral 1,2-diphenyl amino alcohol provided the best results, giving an 80% yield with >20 : 1 dr and 99% ee (Table 1, entries 2–6). The evaluation of other chiral borrowing-hydrogen catalysts was continued, but no further improvement was achieved (Table 1, entries 7–9). With the combination of [Cu]/**L5** and [Ru]-**1** as catalysts, several bases, including inorganic bases K_3PO_4 and Na_2CO_3, as well as organic bases DBU and Et_3N, were then applied, and K_3PO_4 provided the desired product **3a** with similar results (Table 1, entry 10). Further solvent screening showed that 1,4-dioxane gave comparable results (Table 1, entries 14–16). Ester group variation in other α-methyl pyridinyl acetates, such as ethyl ester and *tert*-butyl ester, was also investigated; product **3a** could be

Table 1 Optimization of reaction conditions[a]



Entry	[Ru]	L*	Solvent	Yield[b] (%)	dr[c]	ee[d] (%)
1	[Ru]-**1**	**L1**	THF	76	16 : 1	99
2	[Ru]-**1**	**L2**	THF	55	13 : 1	99
3	[Ru]-**1**	**L3**	THF	42	9 : 1	99
4	[Ru]-**1**	**L4**	THF	40	10 : 1	99
5	[Ru]-**1**	**L5**	THF	80	>20 : 1	99
6	[Ru]-**1**	**L6**	THF	52	4 : 1	97
7	[Ru]-**2**	**L5**	THF	74	>20 : 1	99
8	[Ru]-**3**	**L5**	THF	36	>20 : 1	99
9	[Ru]-**4**	**L5**	THF	30	5 : 1	99
10[e]	[Ru]-**1**	**L5**	THF	72	19 : 1	99
11[f]	[Ru]-**1**	**L5**	THF	NR	—	—
12[g]	[Ru]-**1**	**L5**	THF	NR	—	—
13[h]	[Ru]-**1**	**L5**	THF	NR	—	—
14	[Ru]-**1**	**L5**	Toluene	65	14 : 1	99
15	[Ru]-**1**	**L5**	1,4-Dioxane	78	>20 : 1	99
16	[Ru]-**1**	**L5**	DCM	76	16 : 1	99
17[i]	[Ru]-**1**	**L5**	THF	75	18 : 1	99
18[j]	[Ru]-**1**	**L5**	THF	70	3 : 1	95

[a] All reactions were carried on with [Cu]/**L*** (5 mol%), [**Ru***] (2 mol%), 0.6 mmol **1a**, 0.2 mmol **2a** and 0.3 mmol base in 2 mL of solvent for 24–36 h. Cu(I) = $Cu(MeCN)_4PF_6$. [b] Yields refer to isolated yields after chromatography. [c] dr was determined by crude ^1H NMR analysis. [d] ee was determined by HPLC analysis. [e] K_3PO_4 was used as the base. [f] Na_2CO_3 was used as the base. [g] DBU was used as the base. [h] Et_3N was used as the base. [i] Ethyl 2-(pyridin-2-yl)propanoate was used instead of **2a**. [j] *tert*-Butyl 2-(pyridin-2-yl)propanoate was used instead of **2a**.

obtained with decreasing yield and stereoselectivity (Table 1, entries 17 and 18).

Substrate scope study

With the optimal reaction conditions in hand, we focused on the exploration of the substrate scope and generality of this Cu/Ru relay catalyzed cascade reaction. As summarized in Table 2, a variety of α-methyl azaaryl acetates **2** were employed to react with allylic alcohol **1a**. α-Methyl pyridinyl acetates bearing diverse substituents (F, Cl, Br, Ph, and MeO) at different positions on the pyridinyl ring are well tolerated in this transformation, giving the corresponding products **3b–3j** in good yields (62–73%) with high diastereoselectivity (7 : 1–14 : 1 dr) and generally 99% ee (Table 2, entries 1–9). Other α-methyl azaaryl acetate nucleophiles with pyrazinyl or quinolinyl units were also investigated; the expected products **3k–3l** were generated with excellent reaction outcomes (57% yield, 11 : 1 dr, and 98% ee and 67% yield, >20 : 1 dr, and 99% ee; respectively, Table 2, entries 10 and 11). Moreover, a wide range of α-pyridinyl acetates bearing various alkyl substituted groups on the α-carbon, including aryl, cyclopropyl, alkenyl, and imide groups, were subjected to this transformation, giving the desired products **3m–3r** in good yields with a high level of stereoselective control (65–82% yields, 4 : 1–>20 : 1 dr, and 87–99% ee, Table 2, entries 12–17). Remarkably, the cyclic azaaryl acetate **2s** was well tolerated as the reaction partner, giving the desired product **3s** containing a unique α-spiro-quaternary stereocenter in good yield with excellent diastereo/enantioselectivity (78% yield, >20 : 1 dr, and 99% ee, Table 2, entry 18), which is an important scaffold in medicinal chemistry.[22] Methyl 2-(pyridin-3-yl) and methyl 2-(pyridin-4-yl)propanoate were examined under the standard reaction conditions, and poor conversion was observed without formation of the desired products, demonstrating that the 2-(pyridin-2-yl) moiety in substrate **2** played a key role in enhancing the reactivity.

Having investigated the substrate generality of α-azaaryl acetates, we turned our attention to the examination of this Cu/Ru relay catalysis with regard to allylic alcohols (Table 3). The racemic allylic alcohols **1** bearing different electron-deficient (F, Br, CF_3, and CO_2Me) or electron-donating (Me and MeO) substituted groups on the phenyl ring underwent this cascade reaction smoothly, giving the corresponding δ-valerolactone products (**3t–3D**) in 55–73% yields with 6 : 1–19 : 1 dr and generally with 99% ee (Table 3, entries 1–11). It was found that the position of the substituted groups has a negligible effect on the reaction results. Encouraged by these promising results, sterically constrained 2-naphthyl and 1-naphthyl substituted allylic alcohols were also tested in this protocol as suitable reaction partners, providing the corresponding products **3E** and **3F** in good yields with excellent stereoselectivities (Table 3, entries 12 and 13). The allylic alcohols containing heteroaromatic rings served as compatible substrates, generating the desired products **3G** and **3H** with satisfactory results (Table 3, entries 14 and 15). The challenging alkyl substituted allylic alcohols were further examined, and the expected product **3I** was obtained in good yield with acceptable diastereoselectivity and excellent enantioselectivity (Table 3, entry 16). The absolute configuration of product **3t** was unequivocally determined to be (3*R*,6*S*) by X-ray diffraction analysis (CCDC 2375149).[23]

Stereodivergent synthesis

The stereodivergence of this cascade protocol was then demonstrated by the orthogonal permutation of the chiral copper catalysts and chiral ruthenium catalysts. As demonstrated in Scheme 2, when the reaction of α-methyl pyridinyl acetate **2a** was conducted with four different catalyst combinations, all four stereoisomers of (3*R*,6*S*)-, (3*R*,6*R*)-, (3*S*,6*S*)-, and (3*S*,6*R*)-**3a** could be readily obtained in good yields with high diastereoselectivities and excellent enantioselectivity,

Table 2 Substrate scope study of α-azaaryl acetates[a]



[a] All reactions were carried on with [Cu]/(S,S_p)-**L5** (5 mol%), [Ru]-**1** (2 mol%), 0.6 mmol **1a**, 0.2 mmol **2** and 0.3 mmol Cs_2CO_3 in 2 mL of THF for 36 h. Cu(I) = $Cu(MeCN)_4PF_6$. Yields refer to isolated yields after chromatography. dr was determined by crude ^{1}H NMR analysis. ee was determined by HPLC analysis.

Table 3 Substrate scope study of branched allylic alcohols[a]

Entry	R	3	Yield[b] (%)	dr[c]	ee[d] (%)
1	4-FC_6H_4	**3t**	65	18 : 1	99
2	4-BrC_6H_4	**3u**	68	12 : 1	99
3	4-$CF_3C_6H_4$	**3v**	55	7 : 1	99
4	4-$CO_2MeC_6H_4$	**3w**	60	10 : 1	99
5	4-MeC_6H_4	**3x**	73	14 : 1	99
6	4-$OMeC_6H_4$	**3y**	67	11 : 1	99
7	3-MeC_6H_4	**3z**	62	9 : 1	99
8	3-FC_6H_4	**3A**	57	6 : 1	99
9	2-MeC_6H_4	**3B**	61	19 : 1	99
10	2-FC_6H_4	**3C**	64	14 : 1	99
11	3,5-$Cl_2C_6H_3$	**3D**	66	9 : 1	99
12	2-Naphthyl	**3E**	81	18 : 1	99
13	1-Naphthyl	**3F**	71	16 : 1	99
14	3-Thienyl	**3G**	70	8 : 1	99
15	3-Furyl	**3H**	65	8 : 1	99
16	Cyclohexyl	**3I**	60	3 : 1	98

[a] All reactions were carried out with [Cu]/(S,S_p)-**L5** (5 mol%), [Ru]-**1** (2 mol%), 0.6 mmol **1**, 0.2 mmol **2a** and 0.3 mmol Cs_2CO_3 in 2 mL of THF for 36 h. Cu(I) = $Cu(MeCN)_4PF_6$. [b] Yields refer to isolated yields after chromatography. [c] dr was determined by crude ^{1}H NMR analysis. [d] ee was determined by HPLC analysis.

respectively. Likewise, the precise synthesis of all four stereoisomers of spiro heterocyclic **3s** could also be realized in good yields with decent diastereoselectivities and nearly perfect enantioselectivity. These promising stereodivergence results provide strong evidence to support that each chiral catalyst in this bimetallic Cu/Ru relay catalytic system can independently control the stereochemistry of both the proceeding Michael addition and the subsequent reductive hydrogenation in this cascade protocol.

Scale-up experiments and synthetic application

To showcase the synthetic utility of this protocol, the scale-up experiment and synthetic elaborations were then performed. As depicted in Scheme 3a, the reaction between model substrates phenyl allylic alcohol **1a** and α-methyl pyridinyl acetate **2a** at a 2 mmol scale was carried out under standard conditions, and the chiral product (3*R*,6*S*)-**3a** was obtained in high yield with preserved diastereoselectivity and enantioselectivity (75% yield, >20 : 1 dr, and 99% ee). The lactone group in (3*R*,6*S*)-**3a** could be reduced by $LiAlH_4$ to afford chiral 1,5-diol **4** in 78% yield with >20 : 1 dr and 99% ee. Treatment of (3*R*,6*S*)-**3a** with the methyl Grignard reagent delivered another chiral 1,5-diol **5** in good yield without loss of stereoselectivity. The pyridinyl moiety in **3a** was easily oxidized by *m*-chloroperoxybenzoic acid (*m*-CPBA), affording pyridine-*N*-oxide **6** in 80% yield as a single stereoisomer. Alcoholysis of (3*R*,6*S*)-**3a** in methanol occurred smoothly at room temperature, and the corresponding ring-opening δ-hydroxyl α-methyl azaaryl acetate **7** could be readily isolated as a stable compound in 90% yield without any loss of diastereoselectivity and enantioselectivity. The Mitsunobu reaction of **7** provided enantioenriched azide derivative **8** in a highly stereospecific manner, and the subsequent cascade



Scheme 2 Stereodivergence demonstration.



Scheme 3 Scale-up experiment and synthetic elaborations.

Staudinger reduction/lactamization delivered chiral δ-valerolactam[24] **9** in high yield (Scheme 3b).

Mechanistic studies

A series of control experiments were carried out to gain some mechanistic insights into this dual Cu/Ru relay catalysis. As displayed in Scheme 4a, no reaction occurred when the model reaction was conducted in the absence of the chiral redox ruthenium catalyst. On the other hand, when the reaction was carried out without the chiral copper complex, the process became messy, and the redox process occurred on vinyl phenyl carbinol to afford a mixture of propiophenone **VII** and 1-phenyl-1-propanol **VIII**. These experimental results verified that these two chiral metal catalysts were indispensable in this cascade transformation. Control experiments with allyl methyl ether **10** and tertiary allylic alcohol **11** were conducted, and no conversion was observed under standard reaction conditions (Scheme 4b). Furthermore, the deuterium labeling experiment using allylic alcohol D-**1a** as the substrate was further performed under standard reaction conditions, and the target product D-**3a** containing 94% deuterium at the tertiary carbon stereocenter was observed. The similar deuterated ratio, with preserved diastereoselectivity and enantioselectivity control, supported



reaction conditions	yield (%)
THF, rt, 16 h	trace
Cs_2CO_3 (1.5 eq.), THF, rt, 16 h	87
[Ru]-**1** (2 mol %), THF, rt, 16 h	trace
[Ru]-**1** (2 mol %), Cs_2CO_3 (1.5 eq.), THF, rt, 16 h	89
$Cu(MeCN)_4PF_6$ (5 mol %), THF, rt, 16 h	27
$Cu(MeCN)_4PF_6$ (5 mol %), Cs_2CO_3 (1.5 eq.), THF, rt, 16 h	93
$Cu(MeCN)_4PF_6/(S,S_p)$-**L5** (5 mol %), THF, rt, 16 h	trace
$Cu(MeCN)_4PF_6/(S,S_p)$-**L5** (5 mol %), Cs_2CO_3 (1.5 eq.), THF, rt, 16 h	79

Scheme 4 Mechanistic investigation and control experiments.

the designed relay catalysis *via* orthogonally merging borrowing hydrogen and Michael addition. In addition, the Michael addition between 1-phenylprop-2-en-1-one **II** and α-methyl pyridinyl acetate **2a** was conducted in the presence of Cu/(S,S_p)-**L5**, and the corresponding adduct **12** could be obtained in 76% yield with 90% ee (Scheme 4c), which demonstrated that 1-phenylprop-2-en-1-one **II** was the active intermediate in this redox neutral process. As for the subsequent lactonization, which was supposed to occur spontaneously, the isolation of δ-hydroxyester **7** as a stable ring-opening molecule from δ-hydroxyester **3a** (*vide supra*) forced us to scrutinize this intramolecular transesterification. The control experimental results tabulated in Scheme 4d revealed that the base Cs_2CO_3 plays a key role in this lactonization, serving as an efficient promoter to convert the intermediacy of δ-hydroxyester to the final chiral δ-valerolactone.

Conclusions

In conclusion, we have successfully developed a novel multi-catalytic strategy for the expedient synthesis of biologically important chiral δ-valerolactones bearing 1,4-nonadjacent stereocenters with key features such as atom/step economy and redox-neutrality. The current method relies on orthogonally merging hydrogen borrowing and Michael addition reactions between α-azaaryl acetates and allylic alcohols, enabled by Cu/Ru-relay catalysis, followed by base-promoted lactonization in a one-pot manner, while tolerating a broad substrate scope with the highly functionalized δ-valerolactones being modularly assembled in good to high yields with excellent stereoselective control. The cascade protocol provides a conceptually novel pathway for the stereodivergent synthesis of all four stereoisomers of otherwise inaccessible δ-valerolactones bearing a unique azaarene-containing α-quaternary and a tertiary stereocenter. Considering the prominence of δ-valerolactones, all-carbon quaternary stereocenters, and pyridine moieties in medicinal chemistry, we anticipate that this stereodivergent cascade protocol will be useful for the preparation of the related complex molecules.

Data availability

All experimental procedures, characterisation data, mechanistic investigations, NMR spectra and HPLC spectra can be found in the ESI.†

Author contributions

C. J. W. conceptualized the project. C. J. W. and X. Q. D. supervised the investigation. K. T., Z. J., X. L. L., L. H., H. F. L., P. K. Y., and X. C. performed the research. C. J. W., X. Q. D. and K. T. co-wrote the paper. All authors analyzed the data, discussed the results, and commented on the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the National Key R&D Program of China (2023YFA1506700), NSFC (22071186, 22071187, 22101216, 22271226, and 22371216), and National Youth Talent Support Program. The authors also thank the team at the Core Research Facilities of CCMS (WHU) for assistance in X-ray analysis.

Notes and references

1 (*a*) F. Lovering, J. Bikker and C. Humblet, *J. Med. Chem.*, 2009, **52**, 6752–6756; (*b*) T. T. Talele, *J. Med. Chem.*, 2020, **63**, 13291–13315; (*c*) M. Aldeghi, S. Malhotra, D. L. Selwood and A. W. Chan, *Chem. Biol. Drug Des.*, 2014, **83**, 450–461; (*d*) W. R. Galloway, A. Isidro-Llobet and D. R. Spring, *Nat. Commun.*, 2010, **1**, 80.

2 (*a*) T. Haffner, A. Nordsieck and R. Tressl, *Helv. Chim. Acta*, 1996, **79**, 2088–2099; (*b*) B. Zhang, Y. Zhao, Z. Huang, K. Zhang, X. Xu, Q. Zhao and X. Zhang, *Nat. Prod. Res.*, 2023, **37**, 2144–2150; (*c*) S. Saito, Y. Xiaohanyao, T. Zhou, J. Nakajima-Shimada, E. Tashiro, D. W. Triningsih, E. Harunari, N. Oku and Y. Igarashi, *J. Nat. Prod.*, 2022, **85**, 1697–1703.

3 Y. Kato, Y. Ogawa, T. Imada, S. Iwasaki, N. Shimazaki, T. Kobayashi and T. Komai, *J. Antibiot.*, 1991, **44**, 66–75.

4 F. E. Boyer, J. V. N. Vara Prasad, J. M. Domagala, E. L. Ellsworth, C. Gajda, S. E. Hagen, L. J. Markoski, B. D. Tait, E. A. Lunney, A. Palovsky, D. Ferguson, N. Graham, T. Holler, D. Hupe, C. Nouhan, P. J. Tummino, A. Urumov, E. Zeikus, G. Zeikus, S. J. Gracheck, J. M. Sanders, S. VanderRoest, J. Brodfuehrer, K. Iyer, M. Sinz, S. V. Gulnik and J. W. Erickson, *J. Med. Chem.*, 2000, **43**, 843–858.

5 (*a*) X.-P. Fang, J. E. Anderson, C.-J. Chang, J. L. McLaughlin and P. E. Fanwick, *J. Nat. Prod.*, 1991, **54**, 1034–1043; (*b*) D. S. Lewy, C.-M. Gauss, D. R. Soenen and D. L. Boger, *Curr. Med. Chem.*, 2002, **9**, 2005–2032; (*c*) S. J. Shaw, K. F. Sundermann, M. A. Burlingame, D. C. Myles, B. S. Freeze, M. Xian, I. Brouard and A. B. Smith, *J. Am. Chem. Soc.*, 2005, **127**, 6532–6533; (*d*) M. Kobayashi, K. Higuchi, N. Murakami, H. Tajima and S. Aoki, *Tetrahedron Lett.*, 1997, **38**, 2859–2862.

6 A. Endo, *J. Med. Chem.*, 1985, **28**, 401–405.

7 E. S. Istvan and J. Deisenhofer, *Science*, 2001, **292**, 1160–1164.

8 (*a*) S. R. Martin and D. E. Guinn, *Synthesis*, 1991, 245–262; (*b*) J. Mulzer and E. Öhler, *Chem. Rev.*, 2003, **103**, 3753–3786.

9 (*a*) I. Collins, *J. Chem. Soc., Perkin Trans. 1*, 1999, 1377–1396; (*b*) V. Boucard, G. Broustal and J. M. Campagne, *Eur. J. Org Chem.*, 2007, 225–236.

10 (*a*) P. S. Tiseni and R. Peters, *Angew. Chem., Int. Ed.*, 2007, **46**, 5325–5328; (*b*) G. Bluet, B. Bazán-Tejeda and J.-M. Campagne, *Org. Lett.*, 2001, **3**, 3807–3810; (*c*) D. Enders, J. Vázquez and G. Raabe, *Eur. J. Org Chem.*, 2000, 893–901; (*d*) D. Enders and J. Vázquez, *Synlett*, 1999, 629–631; (*e*) J. H. Smitrovich, G. N. Boice, C. Qu, L. DiMichele, T. D. Nelson, M. A. Huffman, J. Murry,

J. McNamara and P. J. Reider, *Org. Lett.*, 2002, **4**, 1963–1966; (*f*) Y.-Y. Hua, H.-Y. Bin, T. Wei, H.-A. Cheng, Z.-P. Lin, X.-F. Fu, Y.-Q. Li, J.-H. Xie, P.-C. Yan and Q.-L. Zhou, *Org. Lett.*, 2020, **22**, 818–822; (*g*) R. Doran and P. J. Guiry, *Synthesis*, 2014, **46**, 761–770; (*h*) A. Díaz-Rodríguez, W. Borzęcka, I. Lavandera and V. Gotor, *ACS Catal.*, 2014, **4**, 386–393; (*i*) H.-J. Zhang and L. Yin, *J. Am. Chem. Soc.*, 2018, **140**, 12270–12279.

11 (*a*) L. Lin and X. Feng, *Chem.–Eur. J.*, 2017, **23**, 6464–6482; (*b*) G. Zhan, W. Du and Y.-C. Chen, *Chem. Soc. Rev.*, 2017, **46**, 1675–1692; (*c*) S. Krautwald and E. M. Carreira, *J. Am. Chem. Soc.*, 2017, **139**, 5627–5639; (*d*) I. P. Beletskaya, C. Nájera and M. Yus, *Chem. Rev.*, 2018, **118**, 5080–5200; (*e*) L. Wei and C.-J. Wang, *Chin. J. Chem.*, 2021, **39**, 15–24; (*f*) X. Huo, G. Li, X. Wang and W. Zhang, *Angew. Chem., Int. Ed.*, 2022, **61**, e202210086; (*g*) D. Moser, T. A. Schmidt and C. Sparr, *JACS Au*, 2023, **3**, 2612–2630; (*h*) L. Wei, X. Chang, Z. Zhang, Z.-F. Wang and C.-J. Wang, *Chin. Sci. Bull.*, 2023, **68**, 3956–3968; (*i*) H. Wang, Q. Zhang and W. Zi, *Acc. Chem. Res.*, 2024, **57**, 468–488; (*j*) L. Wei, C. Fu, Z.-F. Wang, H.-Y. Tao and C.-J. Wang, *ACS Catal.*, 2024, **14**, 3812–3844.

12 (*a*) K. Jozwiak, W. J. Lough and I. W. Wainer, *Drug Stereochemistry: Analytical Methods and Pharmacology*, CRC Press, Boca Raton, 3rd edn, 2012; (*b*) J. Caldwell, *J. Clin. Pharmacol.*, 1992, **32**, 925–929; (*c*) K. M. Rentsch, *J. Biochem. Biophys. Methods*, 2002, **54**, 1–9; (*d*) B. Waldeck, *Chirality*, 1993, **5**, 350–355.

13 J. He, Z. Li, R. Li, X. Kou, D. Liu and W. Zhang, *Adv. Sci.*, 2024, **11**, 2400621.

14 (*a*) C. M. Marshall, J. G. Federice, C. N. Bell, P. B. Cox and J. T. Njardarson, *J. Med. Chem.*, 2024, **67**, 11622–11655; (*b*) *Pyridines: From lab to Production*, ed. E. F. V. Scriven, Academic Press, Oxford, 2013.

15 For reviews, see: (*a*) Q. Yang, Q. Wang and Z. Yu, *Chem. Soc. Rev.*, 2015, **44**, 2305–2329; (*b*) A. Corma, J. Navas and M. J. Sabater, *Chem. Rev.*, 2018, **118**, 1410–1459; (*c*) T. Irrgang and R. Kempe, *Chem. Rev.*, 2019, **119**, 2524–2549; (*d*) B. G. Reed-Berendt, D. E. Latham, M. B. Dambatta and L. C. Morrill, *ACS Cent. Sci.*, 2021, **7**, 570–585; (*e*) Y. Gao, G. Hong, B.-M. Yang and Y. Zhao, *Chem. Soc. Rev.*, 2023, **52**, 5541–5562, For selected recent examples, see: ; (*f*) B. Lainer, S. Li, F. Mammadova and P. Dydio, *Angew. Chem., Int. Ed.*, 2024, **63**, e202408418; (*g*) Y. Liu, H. Diao, G. Hong, J. Edward, T. Zhang, G. Yang, B.-M. Yang and Y. Zhao, *J. Am. Chem. Soc.*, 2023, **145**, 5007–5016; (*h*) F. Li, L. Long, Y. M. He, Z. Li, H. Chen and Q. H. Fan, *Angew. Chem., Int. Ed.*, 2022, **61**, e202202972.

16 (*a*) L. Wei, Q. Zhu, S.-M. Xu, X. Chang and C.-J. Wang, *J. Am. Chem. Soc.*, 2018, **140**, 1508–1513; (*b*) S.-M. Xu, L. Wei, C. Shen, L. Xiao, H.-Y. Tao and C.-J. Wang, *Nat. Commun.*, 2019, **10**, 5553; (*c*) L. Xiao, L. Wei and C.-J. Wang, *Angew. Chem., Int. Ed.*, 2021, **60**, 24930–24940; (*d*) C. Fu, Q. Xiong, L. Xiao, L. He, T. Bai, Z. Zhang, X.-Q. Dong and C.-J. Wang, *Chin. J. Chem.*, 2022, **40**, 1059–1065; (*e*) L. Xiao, X. Chang, H. Xu, Q. Xiong, Y. Dang and C.-J. Wang, *Angew. Chem., Int. Ed.*, 2022, **61**, e202212948; (*f*) L. Xiao, B. Li, F. Xiao, C. Fu, L. Wei, Y. Dang, X.-Q. Dong and C.-J. Wang, *Chem. Sci.*, 2022, **13**, 4801–4812; (*g*) C. Che, Y. N. Lu and C. J. Wang, *J. Am. Chem. Soc.*, 2023, **145**, 2779–2786; (*h*) B.-K. Zhu, H. Xu, L. Xiao, X. Chang, L. Wei, H. Teng, Y. Dang, X.-Q. Dong and C.-J. Wang, *Chem. Sci.*, 2023, **14**, 4134–4142; (*i*) K. Tian, X. Chang, L. Xiao, X.-Q. Dong and C.-J. Wang, *Fundam. Res.*, 2024, **4**, 77–85.

17 For reviews, see: (*a*) T. L. Lohr and T. J. Marks, *Nat. Chem.*, 2015, **7**, 477–482; (*b*) F. Rudroff, M. D. Mihovilovic, H. Gröger, R. Snajdrova, H. Iding and U. T. Bornscheuer, *Nat. Catal.*, 2018, **1**, 12–22; (*c*) F. Romiti, J. del Pozo, P. H. S. Paioti, S. A. Gonsales, X. Li, F. W. W. Hartrampf and A. H. Hoveyda, *J. Am. Chem. Soc.*, 2019, **141**, 17952–17961; (*d*) S. Martínez, L. Veth, B. Lainer and P. Dydio, *ACS Catal.*, 2021, **11**, 3891–3915; (*e*) D. F. Chen, Z. Y. Han, X. L. Zhou and L. Z. Gong, *Acc. Chem. Res.*, 2014, **47**, 2365–2377; (*f*) D. F. Chen and L. Z. Gong, *J. Am. Chem. Soc.*, 2022, **144**, 2415–2437, For selected recent examples, see: ; (*g*) Y. Liu, Y. Chen, A. Yihuo, Y. Zhou, X. Liu, L. Lin and X. Feng, *ACS Catal.*, 2022, **12**, 1784–1790; (*h*) X. Sang, Y. Mo, S. Li, X. Liu, W. Cao and X. Feng, *Chem. Sci.*, 2023, **14**, 8315–8320; (*i*) W. Wang, F. Zhang, Y. Liu and X. Feng, *Angew. Chem., Int. Ed.*, 2022, **61**, e202208837; (*j*) H. Wang, Y. Xu, F. Zhang, Y. Liu and X. Feng, *Angew. Chem., Int. Ed.*, 2022, **61**, e202115715; (*k*) Z. Wu, X. Yang, F. Zhang, Y. Liu and X. Feng, *Chem. Sci.*, 2024, **15**, 13299–13305; (*l*) M. Chen, L. Yang, Y. Li, Y. Qu, G. Pan, X. Feng and X. Liu, *Sci. China:Chem.*, 2024, **67**, 542–550; (*m*) H. Zheng, Y. Wang, C. Xu, Q. Xiong, L. Lin and X. Feng, *Angew. Chem., Int. Ed.*, 2019, **58**, 5327–5331.

18 (*a*) X. Chang, X. Cheng, X.-T. Liu, C. Fu, W.-Y. Wang and C.-J. Wang, *Angew. Chem., Int. Ed.*, 2022, **61**, e202206517; (*b*) C. Fu, L. He, X. Chang, X. Cheng, Z.-F. Wang, Z.-P. Zhang, V. A. Larionov, X.-Q. Dong and C.-J. Wang, *Angew. Chem., Int. Ed.*, 2024, **63**, e202315325; (*c*) H.-R. Yang, X. Cheng, X. Chang, Z.-F. Wang, X.-Q. Dong and C.-J. Wang, *Chem. Sci.*, 2024, **15**, 10135–10145. For selected examples from other groups, see: ; (*d*) J. Masson-Makdissi, L. Prieto, X. Abel-Snape and M. Lautens, *Angew. Chem., Int. Ed.*, 2021, **60**, 16932–16936; (*e*) D.-X. Zhu, J.-G. Liu and M.-H. Xu, *J. Am. Chem. Soc.*, 2021, **143**, 8583–8589; (*f*) J.-H. Xie, Y.-M. Hou, Z. Feng and S.-L. You, *Angew. Chem., Int. Ed.*, 2023, **62**, e202216396.

19 P. F. Xu and W. Wang, *Catalytic Cascade Reactions*, Wiley-VCH, Weinheim, 2014.

20 (*a*) X.-H. Yang, K. Wang, S.-F. Zhu, J.-H. Xie and Q.-L. Zhou, *J. Am. Chem. Soc.*, 2014, **136**, 17426–17429; (*b*) N. Arai, T. Namba, K. Kawaguchi, Y. Matsumoto and T. Ohkuma, *Angew. Chem., Int. Ed.*, 2018, **57**, 1386–1389.

21 (*a*) B. M. Trost, *Science*, 1991, **254**, 1471–1477; (*b*) P. A. Wender, V. A. Verma, T. J. Paxton and T. H. Pillow, *Acc. Chem. Res.*, 2008, **41**, 40–49; (*c*) N. Z. Burns, P. S. Baran and R. W. Hoffmann, *Angew. Chem., Int. Ed.*, 2009, **48**, 2854–2867.

22 K. Hiesinger, D. Dar'in, E. Proschak and M. Krasavin, *J. Med. Chem.*, 2021, **64**, 150–183.

23 Deposition Number CCDC 2375149 (3*R*,6*S*)-**3t** contains the supplementary crystallo-graphic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service.

24 (*a*) P. A. Reddy, K. E. Woodward, S. M. McIlheran, B. C. H. Hsiang, T. N. Latifi, M. W. Hill, S. M. Rothman, J. A. Ferrendelli and D. F. Covey, *J. Med. Chem.*, 1997, **40**, 44–49; (*b*) X. Zhao, Y. Wu, T. Feng, J. Shen, H. Lu, Y. Zhang, H. H. Chou, X. Luo and J. D. Keasling, *Metab. Eng.*, 2023, 77, 89–99.